Santen Pharmaceutica (SNPHF) 15.3900 $SNPHF
Santen Reports Fiscal 2015 Consolidated Performance
GlobeNewswire - Wed May 11, 3:00AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended March 31, 2016 as well as guidance for fiscal 2016.
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.91 (-0.01), PFE: 35.29 (+0.45), OPHT: 57.40 (+0.25), PFNX: 7.48 (+0.07), OCUL: 6.89 (+0.20), AGN: 250.34 (+0.82), GTXI: 0.65 (unch), OHRP: 3.03 (-0.04), AAVL: 4.14 (-0.18), TCON: 6.72 (-0.27), REGN: 388.04 (-6.43), NVS: 81.43 (-0.18)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 35.29 (+0.45), AMPE: 4.15 (+0.10), DYAX: 38.04 (-0.37), AGN: 250.34 (+0.82), EYEG: 3.18 (-0.02), AAVL: 4.14 (-0.18), OHRP: 3.03 (-0.04), REGN: 388.04 (-6.43)
United States Bacterial Conjunctivitis Drugs Market Study 2015 - Fluoroquinolones to be the Largest Segment by 2024
M2 - Tue Nov 10, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhdchq/the_u_s_market) has announced the addition of the "The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024" report to their offering. The cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013.Thus, potential incidence of bacterial conjunctivitis is one of the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future. Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc.,Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.are the major players operating in the bacterial conjunctivitis drugs market in the U.S. During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment Chapter 6 Recommendations Chapter 7 Company Profiles - Actavis plc (now Allergan plc) - Akorn, Inc. - Bayer AG - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Novartis AG - Perrigo Company plc - Pfizer, Inc. - Santen Pharmaceutical Co., Ltd. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/nh...u_s_market
PRGO: 100.52 (+1.41), AKRX: 31.28 (-0.17), PFE: 35.29 (+0.45), MRK: 57.68 (+0.68), VRX.TO: 30.63 (-0.84), NVS: 81.43 (-0.18)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.81 (+0.04), RIGL: 2.45 (+0.01), OCUL: 6.89 (+0.20), AGN: 250.38 (+0.86), SHPG: 188.91 (-3.11), MRK: 57.68 (+0.68), CLTX: 36.01 (+16.34)
Open-Angle Glaucoma Pipeline Review, H2 2015 - 16 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55m6kn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aerie Pharmaceuticals, Inc. - Allergan Plc - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Oxford BioMedica Plc - Sanofi - Santen Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Sylentis S.A. - vTv Therapeutics LLC Drug Profiles - (carteolol hydrochloride latanoprost) - (dorzolamide hydrochloride latanoprost) - (latanoprost trabodenoson) - AMA-0076 - AR-13324 - ATS-8535 - bamosiran - bimatoprost SR - DE-117 - Glaucoma-GT - HPP-851 - latanoprost - latanoprost SR - latanoprostene bunod - ONO-9054 - OPA-6566 - RO-5093151 - SAR-366234 - Small Molecules to Antagonize CXCR3 for Glaucoma - trabodenoson - travoprost SR For more information visit http://www.researchandmarkets.com/research/55m6kn/openangle
AGN: 250.38 (+0.86), VTVT: 5.99 (+0.04), ITEK: 9.00 (-0.09), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20)
Normal-Tension Glaucoma - Global Clinical Trials Review 2015
M2 - Mon Sep 14, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtf97q/normaltension) has announced the addition of the "Normal-Tension Glaucoma Global Clinical Trials Review, H2, 2015" report to their offering. "Normal-Tension Glaucoma Global Clinical Trials Review, H2, 2015" provides an overview of Normal-Tension Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Normal-Tension Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Companies Mentioned - Pfizer Inc. - Santen Pharmaceutical Co., Ltd. - Nitten Pharmaceutical Co., Ltd. - Merck & Co., Inc. - Kowa Company, Ltd. - Kaken Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/rt...maltension
PFE: 35.29 (+0.45), MRK: 57.68 (+0.68)
Vernal Keratoconjunctivitis - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dphsww/vernal) has announced the addition of the "Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" report to their offering. Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" provides an overview of Vernal Keratoconjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Vernal Keratoconjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Companies Mentioned - Astellas Pharma Inc. - Senju Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Novartis AG - Novagali Pharma SA - Laboratoires Thea S.A. - Funds for Research in Ophthalmology - Chiltern International Limited - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/dphsww/vernal
NVS: 81.43 (-0.18)
Closed-Angle Glaucoma - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38hw2g/closedangle) has announced the addition of the "Closed-Angle Glaucoma Global Clinical Trials Review, H2, 2015" report to their offering. Closed-Angle Glaucoma Global Clinical Trials Review, H2, 2015" provides an overview of Closed-Angle Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Closed-Angle Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T he report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Clinical Trial Overview of Top Companies - Allergan Plc - Santen Pharmaceutical Co., Ltd. - SBI Biotech Co., Ltd. - Novartis AG - Nitten Pharmaceutical Co., Ltd. - Alcon, Inc. - Aerie Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/38...losedangle
AGN: 250.38 (+0.86), AERI: 19.67 (-0.25), NVS: 81.43 (-0.18)
Investigation Report on China's Sodium Hyaluronate Market 2015
PR Newswire Europe - Fri Sep 04, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvzsqg/investigation [http://www.researchandmarkets.com/research/dvzsqg/investigation]) has announced the addition of the "Investigation Report on China's Sodium Hyaluronate Market, 2010-2019" [http://www.researchandmarkets.com/research/dvzsqg/investigation] report to their offering.
Investigation Report on China's Sodium Hyaluronate Market, 2010-2019
M2 - Fri Sep 04, 4:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpkc4n/investigation) has announced the addition of the "Investigation Report on China's Sodium Hyaluronate Market, 2010-2019" report to their offering. Sodium hyaluronate is a long-chain polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. As a major ingredient of synovial fluid and cartilage matrix, sodium hyaluronate can lubricate the joint, protect cartilage of the joint, improve joint contracture and pathological articular fluid. Sodium hyaluronate eye drop is used for the treatment of dry eyes and mechanical lesion to corneal endothelium while sodium hyaluronate injection is used as a joint function-improving agent for intra-articular injection on osteoarthropathy patients. Currently, only sodium hyaluronate injection and eye drop are available in the market. The raw materials of sodium hyaluronate can be classified into pharmaceutical grade, external grade and edible grade. Currently, hyaluronate is mainly used as the raw material of artificial synovial fluid and eye drops after eye surgery which together brought in a global sales value of USD 700-800 million. This figure is estimated to reach up to USD 3 billion if its cosmetics are counted too. In the middle of 1990s, preparations of sodium hyaluronate began to be used in the clinic in China, achieving good efficacy in ophthalmology, orthopaedics and surgery. Sodium hyaluronate develops fast after entering China, annual sales value rising from less than CNY 100 million in 2005 to CNY 290 million in 2014 and CAGR during this period reaching 18.61%. Sodium hyaluronate enjoys a vast demand in China. Seikagaku Corporation (Japan), United Laboratories, Bausch & Lomb, Santen Pharmaceutical Co., Ltd (Japan), Shanghai Jingfeng Pharmaceutical Co., Ltd and URSAPHARM Arzneimittel GmbH Co.KG (GE) all take up certain shares in the market, among of which Seikagaku Corporation (Japan) has the largest market share of 29% for sales value in 2014. Over the last decade, the demand for sodium hyaluronate in the area of health has kept increasing. With the ever-growing demand of life quality and the rapid aging of the urban population, senile diseases like cataract and osteoarthritis, the market size of sodium hyaluronate will continue to expand in China. Companies Mentioned - United Laboratories - Bausch & Lomb - Shanghai Jingfeng Pharmaceutical Co., Ltd - Shanghai Haohai Biological Technology Co., Ltd - Santen Pharmaceutical Co., Ltd (Japan) For more information visit http://www.researchandmarkets.com/research/zp...estigation
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.95 (-0.02), AGN: 250.38 (+0.86), ITEK: 9.00 (-0.09), MRK: 57.69 (+0.69), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20)
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 3.46 (+0.01), TRVN: 7.47 (+0.01), KMPH: 7.30 (+0.01), AVXL: 4.50 (-0.14), MRK: 57.69 (+0.69), PCRX: 46.96 (-1.23), NKTR: 16.09 (+0.08)
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. ("Santen"
announced today that it has resolved at its board of directors meeting held on May 12, 2015 to enter an agreement with Showa Yakuhin Kakou Co., Ltd. ("Showa Yakuhin" and Hyperion Pharma Co., Ltd. ("Hyperion" to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan ("Assignment" . On the same date, Santen, Hyperion, and Showa have entered into the agreement on the Assignment.
Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015) as well as guidance for fiscal 2015 (ending March 31, 2016).
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
GlobeNewswire - Mon Mar 02, 2:24AM CST
Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment. The MAA filing marks the beginning of a regulatory review process for intravitreal sirolimus, which has the potential to address an unmet need in the European Union (EU) where NIU of the posterior segment is a leading cause of blindness.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 8.47 (+0.01), ITEK: 9.00 (-0.09), NBS: 2.25 (-0.09), FOMX: 7.11 (unch), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20), AGN: 250.38 (+0.86), CANF: 2.95 (-0.02), ACAD: 41.56 (+0.98), GILD: 87.53 (+0.03), MRK: 57.69 (+0.69), TEVA: 53.96 (-0.10), OHRP: 3.03 (-0.04), CBMG: 15.40 (+0.18)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.39 (+0.01)
Santen Reports Fiscal 2015 Consolidated Performance
GlobeNewswire - Wed May 11, 3:00AM CDT
Santen Pharmaceutical Co., Ltd. (Osaka, JAPAN, Tokyo Stock Exchange Code 4536) (Santen) today announced consolidated performance for fiscal 2015 ended March 31, 2016 as well as guidance for fiscal 2016.
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.91 (-0.01), PFE: 35.29 (+0.45), OPHT: 57.40 (+0.25), PFNX: 7.48 (+0.07), OCUL: 6.89 (+0.20), AGN: 250.34 (+0.82), GTXI: 0.65 (unch), OHRP: 3.03 (-0.04), AAVL: 4.14 (-0.18), TCON: 6.72 (-0.27), REGN: 388.04 (-6.43), NVS: 81.43 (-0.18)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 35.29 (+0.45), AMPE: 4.15 (+0.10), DYAX: 38.04 (-0.37), AGN: 250.34 (+0.82), EYEG: 3.18 (-0.02), AAVL: 4.14 (-0.18), OHRP: 3.03 (-0.04), REGN: 388.04 (-6.43)
United States Bacterial Conjunctivitis Drugs Market Study 2015 - Fluoroquinolones to be the Largest Segment by 2024
M2 - Tue Nov 10, 8:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/nhdchq/the_u_s_market) has announced the addition of the "The U.S Market Study on Bacterial Conjunctivitis Drugs: Fluoroquinolones to be the Largest Segment by 2024" report to their offering. The cost of treating bacterial conjunctivitis ranges from USD 377 million to USD 857 million annually in the U.S It also quoted that majority of conjunctivitis patients are originally treated by primary care physicians rather than eye care professionals. Around 1% of all primary care office visits in the U.S. are related to conjunctivitis. Bacterial infestation is the second most common cause of infectious conjunctivitis and accounts for 50% to 75% cases among children. This pattern was observed more frequently from December 2012 to April 2013.Thus, potential incidence of bacterial conjunctivitis is one of the major drivers of the bacterial conjunctivitis drugs market in the U.S. However, increasing genericization of antibacterial drugs coupled with upcoming patent expirations,and such few prominent factors are weakening the growth of the market in the near future. Currently, the market is highly fragmented and competitive due to the involvement of both large and small pharmaceutical companies. Actavis plc (now Allergan plc), Akorn, Inc.,Bayer AG, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Perrigo Company plc, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., and Valeant Pharmaceuticals International, Inc.are the major players operating in the bacterial conjunctivitis drugs market in the U.S. During the course of this study it has been observed that majority of the players are focusing on expanding their geographical reach and distribution network through mergers and acquisitions as well as through collaborations with other potential organizations operating in this market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 U.S. Bacterial Conjunctivitis Drugs Market Overview Chapter 4 U.S. Bacterial Conjunctivitis Drugs Market, by Drug Class Chapter 5 U.S. Bacterial Conjunctivitis Drugs Market, Pipeline Assessment Chapter 6 Recommendations Chapter 7 Company Profiles - Actavis plc (now Allergan plc) - Akorn, Inc. - Bayer AG - F. Hoffmann-La Roche Ltd. - Merck & Co., Inc. - Novartis AG - Perrigo Company plc - Pfizer, Inc. - Santen Pharmaceutical Co., Ltd. - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/nh...u_s_market
PRGO: 100.52 (+1.41), AKRX: 31.28 (-0.17), PFE: 35.29 (+0.45), MRK: 57.68 (+0.68), VRX.TO: 30.63 (-0.84), NVS: 81.43 (-0.18)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttwz6m/keratoconjunctivit) has announced the addition of the "Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Allergan Plc - Celsus Therapeutics Plc - Circadian Technologies Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - HanAll Biopharma Co., Ltd. - Herantis Pharma plc. - Huons Co., Ltd. - InSite Vision Incorporated - Kala Pharmaceuticals, Inc. - Kissei Pharmaceutical Co., Ltd. - Laboratorios Sophia S.A. de C.V. - Lee's Pharmaceutical Holdings Limited - Lipicard Technologies Limited - LTT Bio-Pharma Co., Ltd. - Merck & Co., Inc. - Mimetogen Pharmaceuticals Inc. - Nanomerics Ltd - Neuroptis Biotech - Novaliq GmbH - Ocular Therapeutix, Inc. - OncoNOx ApS - Otsuka Holdings Co., Ltd. - Parion Sciences, Inc. - R-Tech Ueno, Ltd. - RegeneRx Biopharmaceuticals, Inc. - Resolvyx Pharmaceuticals, Inc - Rigel Pharmaceuticals, Inc. - Samjin Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Scynexis, Inc. - Seikagaku Corporation - Shire Plc - TearSolutions, LLC. - Vertex Pharmaceuticals Incorporated For more information visit http://www.researchandmarkets.com/research/tt...njunctivit
VRTX: 94.81 (+0.04), RIGL: 2.45 (+0.01), OCUL: 6.89 (+0.20), AGN: 250.38 (+0.86), SHPG: 188.91 (-3.11), MRK: 57.68 (+0.68), CLTX: 36.01 (+16.34)
Open-Angle Glaucoma Pipeline Review, H2 2015 - 16 Companies & 21 Drug Profiles
M2 - Wed Oct 07, 3:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/55m6kn/openangle) has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Open-Angle Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Open-Angle Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aerie Pharmaceuticals, Inc. - Allergan Plc - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Oxford BioMedica Plc - Sanofi - Santen Pharmaceutical Co., Ltd. - Sun Pharmaceutical Industries Limited - Sylentis S.A. - vTv Therapeutics LLC Drug Profiles - (carteolol hydrochloride latanoprost) - (dorzolamide hydrochloride latanoprost) - (latanoprost trabodenoson) - AMA-0076 - AR-13324 - ATS-8535 - bamosiran - bimatoprost SR - DE-117 - Glaucoma-GT - HPP-851 - latanoprost - latanoprost SR - latanoprostene bunod - ONO-9054 - OPA-6566 - RO-5093151 - SAR-366234 - Small Molecules to Antagonize CXCR3 for Glaucoma - trabodenoson - travoprost SR For more information visit http://www.researchandmarkets.com/research/55m6kn/openangle
AGN: 250.38 (+0.86), VTVT: 5.99 (+0.04), ITEK: 9.00 (-0.09), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20)
Normal-Tension Glaucoma - Global Clinical Trials Review 2015
M2 - Mon Sep 14, 5:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtf97q/normaltension) has announced the addition of the "Normal-Tension Glaucoma Global Clinical Trials Review, H2, 2015" report to their offering. "Normal-Tension Glaucoma Global Clinical Trials Review, H2, 2015" provides an overview of Normal-Tension Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Normal-Tension Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Companies Mentioned - Pfizer Inc. - Santen Pharmaceutical Co., Ltd. - Nitten Pharmaceutical Co., Ltd. - Merck & Co., Inc. - Kowa Company, Ltd. - Kaken Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/rt...maltension
PFE: 35.29 (+0.45), MRK: 57.68 (+0.68)
Vernal Keratoconjunctivitis - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dphsww/vernal) has announced the addition of the "Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" report to their offering. Vernal Keratoconjunctivitis Global Clinical Trials Review, H2, 2015" provides an overview of Vernal Keratoconjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Vernal Keratoconjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Companies Mentioned - Astellas Pharma Inc. - Senju Pharmaceutical Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Novartis AG - Novagali Pharma SA - Laboratoires Thea S.A. - Funds for Research in Ophthalmology - Chiltern International Limited - Ajanta Pharma Limited For more information visit http://www.researchandmarkets.com/research/dphsww/vernal
NVS: 81.43 (-0.18)
Closed-Angle Glaucoma - Global Clinical Trials Review, H2, 2015
M2 - Thu Sep 10, 6:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38hw2g/closedangle) has announced the addition of the "Closed-Angle Glaucoma Global Clinical Trials Review, H2, 2015" report to their offering. Closed-Angle Glaucoma Global Clinical Trials Review, H2, 2015" provides an overview of Closed-Angle Glaucoma clinical trials scenario. This report provides top line data relating to the clinical trials on Closed-Angle Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T he report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using a proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Clinical Trial Overview of Top Companies - Allergan Plc - Santen Pharmaceutical Co., Ltd. - SBI Biotech Co., Ltd. - Novartis AG - Nitten Pharmaceutical Co., Ltd. - Alcon, Inc. - Aerie Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/38...losedangle
AGN: 250.38 (+0.86), AERI: 19.67 (-0.25), NVS: 81.43 (-0.18)
Investigation Report on China's Sodium Hyaluronate Market 2015
PR Newswire Europe - Fri Sep 04, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dvzsqg/investigation [http://www.researchandmarkets.com/research/dvzsqg/investigation]) has announced the addition of the "Investigation Report on China's Sodium Hyaluronate Market, 2010-2019" [http://www.researchandmarkets.com/research/dvzsqg/investigation] report to their offering.
Investigation Report on China's Sodium Hyaluronate Market, 2010-2019
M2 - Fri Sep 04, 4:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpkc4n/investigation) has announced the addition of the "Investigation Report on China's Sodium Hyaluronate Market, 2010-2019" report to their offering. Sodium hyaluronate is a long-chain polymer containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. As a major ingredient of synovial fluid and cartilage matrix, sodium hyaluronate can lubricate the joint, protect cartilage of the joint, improve joint contracture and pathological articular fluid. Sodium hyaluronate eye drop is used for the treatment of dry eyes and mechanical lesion to corneal endothelium while sodium hyaluronate injection is used as a joint function-improving agent for intra-articular injection on osteoarthropathy patients. Currently, only sodium hyaluronate injection and eye drop are available in the market. The raw materials of sodium hyaluronate can be classified into pharmaceutical grade, external grade and edible grade. Currently, hyaluronate is mainly used as the raw material of artificial synovial fluid and eye drops after eye surgery which together brought in a global sales value of USD 700-800 million. This figure is estimated to reach up to USD 3 billion if its cosmetics are counted too. In the middle of 1990s, preparations of sodium hyaluronate began to be used in the clinic in China, achieving good efficacy in ophthalmology, orthopaedics and surgery. Sodium hyaluronate develops fast after entering China, annual sales value rising from less than CNY 100 million in 2005 to CNY 290 million in 2014 and CAGR during this period reaching 18.61%. Sodium hyaluronate enjoys a vast demand in China. Seikagaku Corporation (Japan), United Laboratories, Bausch & Lomb, Santen Pharmaceutical Co., Ltd (Japan), Shanghai Jingfeng Pharmaceutical Co., Ltd and URSAPHARM Arzneimittel GmbH Co.KG (GE) all take up certain shares in the market, among of which Seikagaku Corporation (Japan) has the largest market share of 29% for sales value in 2014. Over the last decade, the demand for sodium hyaluronate in the area of health has kept increasing. With the ever-growing demand of life quality and the rapid aging of the urban population, senile diseases like cataract and osteoarthritis, the market size of sodium hyaluronate will continue to expand in China. Companies Mentioned - United Laboratories - Bausch & Lomb - Shanghai Jingfeng Pharmaceutical Co., Ltd - Shanghai Haohai Biological Technology Co., Ltd - Santen Pharmaceutical Co., Ltd (Japan) For more information visit http://www.researchandmarkets.com/research/zp...estigation
Ocular Hypertension - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nbvbk4/ocular) has announced the addition of the "Ocular Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ocular Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Aerie Pharmaceuticals, Inc. - Allergan, Inc. - Amakem NV - Asahi Kasei Pharma Corp. - Bausch & Lomb Incorporated - Can-Fite BioPharma Ltd. - F. Hoffmann-La Roche Ltd. - Inotek Pharmaceuticals Corporation - Merck & Co., Inc. - Ocular Therapeutix, Inc. - Ono Pharmaceutical Co., Ltd. - Otsuka Holdings Co., Ltd. - Santen Pharmaceutical Co., Ltd. - Sylentis S.A. For more information visit http://www.researchandmarkets.com/research/nbvbk4/ocular
CANF: 2.95 (-0.02), AGN: 250.38 (+0.86), ITEK: 9.00 (-0.09), MRK: 57.69 (+0.69), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20)
Global Acute Pain Pipeline Report 2015
M2 - Thu Jun 04, 8:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gndxls/acute_pain) has announced the addition of the "Acute Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - AcelRx Pharmaceuticals, Inc. - Adynxx, Inc. - AnaBios Corporation - Anavex Life Sciences Corp. - AngioChem Inc. - Antibe Therapeutics, Inc. - Cara Therapeutics, Inc. - Charleston Laboratories, Inc. - ChironWells GmbH - Cytogel Pharma, LLC - Glenmark Pharmaceuticals Ltd. - Grunenthal GmbH - Iroko Pharmaceuticals, LLC - KemPharm, Inc. - Kineta, Inc. - Laboratorios Del Dr. Esteve S.A. - Mallinckrodt plc - MEDRx Co., Ltd. - Merck & Co., Inc. - Nanomerics Ltd - Nektar Therapeutics - Nuvo Research Inc. - Orbis Biosciences, Inc. - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Rottapharm SpA - Santen Pharmaceutical Co., Ltd. - Sigma-Tau S.p.A. - Syntrix Biosystems, Inc. - Thar Pharmaceuticals, Inc. - Trevena, Inc. - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/gndxls/acute_pain
ACRX: 3.46 (+0.01), TRVN: 7.47 (+0.01), KMPH: 7.30 (+0.01), AVXL: 4.50 (-0.14), MRK: 57.69 (+0.69), PCRX: 46.96 (-1.23), NKTR: 16.09 (+0.08)
Santen Announces Assignment of Its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma Co., Ltd.
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. ("Santen"
announced today that it has resolved at its board of directors meeting held on May 12, 2015 to enter an agreement with Showa Yakuhin Kakou Co., Ltd. ("Showa Yakuhin" and Hyperion Pharma Co., Ltd. ("Hyperion" to assign its anti-rheumatic pharmaceuticals business to Hyperion, under a simplified company-split method under the Company Act of Japan ("Assignment" . On the same date, Santen, Hyperion, and Showa have entered into the agreement on the Assignment. Santen Reports Consolidated Performance for the Fiscal Year Ended March 31, 2015
GlobeNewswire - Tue May 12, 2:53AM CDT
Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange Code:4536) (Santen) today announced consolidated performance for fiscal 2014 (ended March 31, 2015) as well as guidance for fiscal 2015 (ending March 31, 2016).
European Medicines Agency Accepts Santen's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment
GlobeNewswire - Mon Mar 02, 2:24AM CST
Santen Pharmaceutical Co., Ltd. announced that the European Medicines Agency (EMA) has accepted the company's Marketing Authorization Application (MAA) filing for the use of intravitreal sirolimus, an investigational mTOR inhibitor, for the treatment of noninfectious uveitis (NIU) of the posterior segment. The MAA filing marks the beginning of a regulatory review process for intravitreal sirolimus, which has the potential to address an unmet need in the European Union (EU) where NIU of the posterior segment is a leading cause of blindness.
Glaucoma Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 11:30AM CST
The report "Glaucoma - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Glaucoma. Glaucoma is caused because of the pressure inside the eye. The primary function of the optic nerve is to send images to the brain. Permanent loss of vision can occur if this optic nerve gets damaged. If not treated on time total permanent blindness might occur. Proper precautions (like visiting an eye doctor) must be taken. The disease can be inherited and if any member of the family is found to be having glaucoma then immediately go for checking. Complete Report is Available @ http://www.rnrmarketresearch.com/glaucoma-pip...eport.html .
OCAT: 8.47 (+0.01), ITEK: 9.00 (-0.09), NBS: 2.25 (-0.09), FOMX: 7.11 (unch), AERI: 19.67 (-0.25), OCUL: 6.89 (+0.20), AGN: 250.38 (+0.86), CANF: 2.95 (-0.02), ACAD: 41.56 (+0.98), GILD: 87.53 (+0.03), MRK: 57.69 (+0.69), TEVA: 53.96 (-0.10), OHRP: 3.03 (-0.04), CBMG: 15.40 (+0.18)
DURECT Enters into License Agreement Granting Santen the Worldwide Rights to a Sustained Release SABER® Ophthalmology Product
PR Newswire - Tue Dec 16, 7:00AM CST
DURECT Corporation (Nasdaq: DRRX) announced today that it has entered into an agreement with Santen Pharmaceutical Co., Ltd. granting Santen the exclusive worldwide rights to develop and commercialize a sustained release product utilizing DURECT's SABER® technology to deliver an ophthalmology drug.
DRRX: 1.39 (+0.01)
